Cargando…
Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells
Failed T cell-based immunotherapies in the presence of genomic alterations in antigen presentations pathways may be overcome by NK cell-based immunotherapy. This approach may still be limited by the presence of immunosuppressive myeloid populations. Here, we demonstrate that NK cells (haNKs) enginee...
Autores principales: | Robbins, Yvette, Greene, Sarah, Friedman, Jay, Clavijo, Paul E, Van Waes, Carter, Fabian, Kellsye P, Padget, Michelle R, Abdul Sater, Houssein, Lee, John H, Soon-Shiong, Patrick, Gulley, James, Schlom, Jeffrey, Hodge, James W, Allen, Clint T |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340502/ https://www.ncbi.nlm.nih.gov/pubmed/32633234 http://dx.doi.org/10.7554/eLife.54854 |
Ejemplares similares
-
Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells
por: Lee, Maxwell Y, et al.
Publicado: (2021) -
PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations
por: Fabian, Kellsye P, et al.
Publicado: (2020) -
Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis
por: Robbins, Yvette, et al.
Publicado: (2021) -
Overcoming hypoxia-induced functional suppression of NK cells
por: Solocinski, Kristen, et al.
Publicado: (2020) -
Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve
por: Fabian, Kellsye P, et al.
Publicado: (2021)